Stockscreener 앱 받기
15.31
4.08%
0.60
시간 외 거래:
15.20
-0.11
-0.72%
Uniqure N V 주식(QURE)의 최신 뉴스
(QURE) Trading Advice - news.stocktradersdaily.com
Wall Street Analysts See a 161.51% Upside in uniQure (QURE): Can the Stock Really Move This High? - Yahoo Finance
uniQure (NASDAQ:QURE) Given Average Recommendation of “Moderate Buy” by Analysts - Defense World
uniQure N.V. (NASDAQ:QURE) Q1 2025 Earnings Call Transcript - Insider Monkey
uniQure (NASDAQ:QURE) Receives Buy Rating from Guggenheim - Defense World
uniQure’s (QURE) Buy Rating Reaffirmed at Chardan Capital - Defense World
uniQure N.V. Earnings Call: Progress Amid Challenges - TipRanks
uniQure (QURE) Stock Rating Reaffirmed by Guggenheim | QURE Stoc - GuruFocus
uniQure (QURE) Remains a Strong Buy with Price Target Maintained at $38 | QURE Stock News - GuruFocus
uniQure Announces First Quarter 2025 Financial Results and Highlights of Recent Company Progress - ADVFN
Is uniQure (NASDAQ:QURE) A Risky Investment? - simplywall.st
UniQure: Q1 Earnings Snapshot - New Haven Register
Uniqure NV earnings beat by $0.18, revenue fell short of estimates - Investing.com India
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... - Yahoo Finance
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating R - GuruFocus
uniQure NV (QURE) Q1 2025 Earnings Call Highlights: Navigating Revenue Decline with Strategic ... By GuruFocus - Investing.com Canada
uniQure NV Reports Q1 2025 Earnings: EPS Loss of $0.82 Beats Est - GuruFocus
Transcript : UniQure N.V., Q1 2025 Earnings Call, May 09, 2025 - marketscreener.com
QURE's Financial Position Strengthened by Recent Capital Raise | - GuruFocus
uniQure (QURE) Reports Lower Q1 Revenue, Advances Huntington's T - GuruFocus
uniQure Q1 2025 Earnings Call Transcript - MarketBeat
UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode By Stocktwits - Investing.com India
UniQure Narrows Q1 Loss But Revenue Plummets: Retail’s In Wait-And-Watch Mode - NewsBreak: Local News & Alerts
UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
uniQure NV Reports Q1 2025 Earnings: EPS Loss of $0.82 Beats Estimates, Revenue Falls Short at $1.6 Million - GuruFocus
uniQure Reports Breakthrough Therapy Designation for AMT-130 and Financial Results for Q1 2025 - Nasdaq
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Stifel Financial Corp Has $992,000 Holdings in uniQure (NASDAQ:QURE) - The AM Reporter
Wells Fargo & Company MN Buys 1,503 Shares of uniQure (NASDAQ:QURE) - Defense World
uniQure (QURE) Stock Decline Viewed as Overreaction by Analysts | QURE Stock News - GuruFocus
uniQure: A Buy For Their Lead In Huntington's Program, In Light Of PTC's Data - Seeking Alpha
(QURE) Proactive Strategies - news.stocktradersdaily.com
Uniqure NV expected to post a loss of $1.01 a shareEarnings Preview - TradingView
uniQure (QURE) Receives Steady "Buy" Rating from Chardan Capital - GuruFocus
uniQure to Announce First Quarter 2025 Financial Results - The Manila Times
Gene Therapy Leader uniQure Launches Quarterly Earnings Calls as AMT-130 Nears BLA Submission - Stock Titan
Raymond James Financial Inc. Invests $1.95 Million in uniQure (NASDAQ:QURE) - Defense World
Geode Capital Management LLC Has $9.20 Million Stock Holdings in uniQure (NASDAQ:QURE) - Defense World
UniQure stock holds $70 target, buoyed by FDA breakthrough nod - Investing.com Australia
uniQure (NASDAQ:QURE) Shares Purchased by Invesco Ltd. - Defense World
(QURE) Investment Analysis - news.stocktradersdaily.com
Gene therapy developers rise on comments from FDA's Makary - Seeking Alpha
uniQure (QURE) Moves 38.5% Higher: Will This Strength Last? - Yahoo Finance
uniQure: Huntington's Gene Therapy Advances, But Commercial Hurdles Keep This A Hold - Seeking Alpha
uniQure: Bullish On Near Term Catalysts After Breakthrough Therapy Designation For AMT-130 - Seeking Alpha
uniQure: AMT-130 For HD Progresses Forward With Q2 2025 FDA Meeting - Seeking Alpha
uniQure jumps on FDA breakthrough tag for Huntington’s disease drug - MSN
2.33%
1.09%
자본화:
|
볼륨(24시간):